

# Index

## A

- Acupuncture, 292–293
- Acute bacterial prostatitis, 193–194
- Acute cystitis
  - antibiotics
    - antibiotic resistance, 176, 178
    - combination penicillins, 176
    - fosfomicin, 176
    - nitrofurantoin macrocrystals, 176
    - quinolones and trimethoprim, 176
    - recommendations, 177
    - trimethoprim-sulfamethoxazole, 176
  - repeat urinalysis and culture, 178
  - urinary analgesics, 178
- $\alpha$ -adrenergic receptor blockers, LUTS, 251–252
- American Urologic Association Symptom Index (AUASI), 245
- Amitriptyline, interstitial cystitis, 167
- Anatrophic nephrolithotomy, 77, 80
- Angiokeratomas, 216–218
- Antibiotics
  - acute cystitis
    - antibiotic resistance, 176, 178
    - combination penicillins, 176
    - fosfomicin, 176
    - nitrofurantoin macrocrystals, 176
    - quinolones and trimethoprim, 176
    - recommendations, 177
    - trimethoprim-sulfamethoxazole, 176
  - pregnancy and UTI
    - antimicrobial drugs toxicity, 126
    - bacteriuria, 125–126
    - intrauterine growth restriction, 126
    - nitrofurantoin and sulfonamide, 127
    - preeclampsia, 126
    - risk of prematurity, 126
  - recurrent bacterial cystitis, 180–181
- Antimuscarinic therapy, LUTS, 253
- 5 $\alpha$ -reductase inhibitors, LUTS, 252–253
- Asymptomatic prostatic inflammation, 199–200
- Augmentation cystoplasty, 158
- Ayurveda, 284

## B

- Bacillus-Camille Guerin (BCG) vaccine, 168
- Balanitis xerotica obliterans (BXO), 209, 210
- Bartholin gland duct cyst, 216
- Bladder cancer
  - high-risk groups, 36–37
  - methods of
    - cystoscopy, 37
    - hematuria screening, 37
    - tumor markers, 37–38
    - urine cytology, 37
- Bladder hydrodistension, 165
- Bupivacaine, interstitial cystitis, 168

## C

- Chiropractic medicine, 288
- Chronic pelvic pain syndrome (CPPS)
  - clinical signs and symptoms, 194–195
  - diagnosis, 198–199
  - functional somatic syndrome, 197–198
  - histological changes, 195
  - inflammation, 195
  - non-urological perspectives
    - chemical (noninfectious) prostatitis, 195
    - colorectal surgery, 196
    - nomogram, 196
    - pelvic floor myalgia, 195–196
    - physical therapy, 196
    - pseudodyssynergia, 195
    - voiding dysfunction, 195
  - physiotherapy, 196–197
  - prostatocentric treatments, 194–195
  - treatment, 199
- Complementary and alternative medicine (CAM)
  - energy medicine
    - acupuncture, 292–293
    - homeopathy, 294–295
    - Reiki, 293
    - therapeutic touch, 293–294

- Complementary and alternative medicine (CAM) (*cont.*)
- manipulative and body-based therapy
    - autogenic training, 291
    - biofeedback, 291–292
    - chiropractic medicine, 288
    - dance, 289
    - Feldenkrais method, 290–291
    - massage therapy, 288–289
    - myofascial release, 289
    - tai chi, 290
    - yoga, 289–290
  - mind and body medicine
    - ayurveda, 284
    - expressive meditation, 284–285
    - functional connectivity MRI, 285
    - guided imagery, 286
    - hypnotherapy, 285–286
    - music therapy, 286
    - neuromusicology, 287
    - neurophysiologic effects, 285
    - relaxation therapy, 284
    - spirituality, 287–288
  - natural and behavioral remedies
    - diet, 281–282
    - exercise, 283
    - herbal remedies, 281, 282
    - mindful eating, 282–283
    - sleep, 283–284
  - physician-patient relationship, 280–281
  - placebo effect, 281
  - stress
    - exhaustion, 279–280
    - homeostasis, 279
    - stress recognition and flight response, 278
  - types of
    - herbal remedies, 278
    - holistic care and surgery, 278
    - manipulative and body-based practices, 278
    - mind and body medicine, 277
    - movement therapies, 278
    - natural products, 277
- Computed tomography, 50–51
- adrenal, 56–57
  - hematuria, 70–71
  - hounsfield units (HU), 52
  - kidney, 52–55
  - renal pelvis, ureters, and bladder, 56
  - retroperitoneum, 57
- Congenital absence of the vas deferens (CAVD), 236
- Contact dermatitis, 204
- allergic contact dermatitis
    - allergens, 203–204
    - cause, 203
    - condoms and rubber diaphragms, 203
    - genital contact dermatitis, 203
    - tetramethylthiuram and mercaptobenzothiazole, 203
  - differential diagnosis, 205
  - irritant contact dermatitis, 205
  - Rhus dermatitis, 204–205
  - treatment, 205
- Corynebacterium minutissimum*, 214
- CPPS. *See* Chronic pelvic pain syndrome (CPPS)
- Cystography, 46–47
- D**
- Dance, 289
  - Digital rectal examination (DRE), 29
  - Dimethylsulfoxide (DMSO), interstitial cystitis, 168
  - Diurnal incontinence, 12–13
- E**
- Ectopic pregnancy, 124–125
  - Ejaculatory duct obstruction (EDO), 238
  - Electroejaculation (EEJ), 238–239
  - Energy medicine
    - acupuncture, 292–293
    - homeopathy, 294–295
    - Reiki, 293
    - therapeutic touch, 293–294
  - Erythrasma, 214, 215
  - Expressive meditation, 284–285
  - Extracorporeal shock wave lithotripsy (ESWL), 128
  - Extramammary Paget's disease, 219–220
- F**
- Factitial dermatitis, 223
  - Feldenkrais method, 290–291
  - Female genital mutilation, 223–224
  - Fixed drug eruption, 211, 212
  - Functional connectivity MRI, 285
  - Fungal cystitis, 183
- G**
- Genitourinary (GU) cancer
    - bladder cancer, 36–38
    - DRE, 29
    - kidney cancer, 33–34
    - lead-time bias, 28
    - length-time bias, 28, 29
    - prostate cancer (*see* Prostate cancer)
    - testicular cancer, 38–39
  - Genitourinary dermatology
    - balanitis xerotica obliterans, 209, 210
    - Bartholin gland duct cyst, 216
    - benign growths
      - angiokeratomas, 216–218
      - pearly penile papules, 216, 217
    - contact dermatitis (*see* Contact dermatitis)
    - factitial dermatitis, 223
    - female genital mutilation, 223–224
    - fixed drug eruption, 211, 212
    - idiopathic scrotal calcinosis, 217
    - infections
      - Candida albicans*, 211–213
      - Corynebacterium minutissimum*, 214
      - hidradenitis suppurativa, 214–216
      - tinea cruris, 212–214
    - lichen nitidus, 208

- lichen planus, 207, 208
  - lichen sclerosus, 208–209
  - lichen simplex chronicus (*see* Lichen simplex chronicus)
  - malignant growths
    - extramammary Paget's disease, 219–220
    - melanoma, 220
    - squamous cell carcinoma, 217–219
  - plasma cell balanitis, 209–211
  - sexually transmitted infections
    - herpes simplex virus, 221–222
    - human papillomavirus, 220–222
    - syphilis, 223
- H**
- Hematospermia, 75
  - Hematuria
    - complications of
      - anemia, 74–75
      - urinary clot retention, 75
    - diagnostic testing
      - computed tomography, 70–71
      - cystoscopy, 72–73
      - cytology, 68
      - intravenous pyelography, 69–70
      - magnetic resonance imaging, 71–72
      - plain abdominal film, 69
      - renal arteriography, 71
      - retrograde pyelography, 72
      - urinalysis, 67–68
    - initial and subsequent evaluation, 73–74
    - patient history
      - blood spots, 65
      - menstruation, 66
      - microhematuria, 65–66
      - sexual history, 66
      - terminal, 66
    - physical examination
      - abdominal, 66
      - bowel sounds, 66–67
      - female genital examination, 67
      - male genital examination, 67
    - special situations
      - anatomic nephrolithotomy, 77, 80
      - filling defect, 75, 77
      - hematospermia, 75
      - hydronephrosis, 75, 77, 78, 82
      - lower pole collecting system, visualization, 75, 76
      - renal staghorn calculus, 77, 79
      - upper collecting system effacement, 77, 84
- Herbal remedies, 281, 282
  - Herbal therapy, LUTS, 251
  - Herpes simplex virus (HSV) infection, 221–222
  - Hidradenitis suppurativa (HS), 214–216
  - Holmium laser enucleation of the prostate (HoLEP), 255
  - Homeopathy, 294–295
  - Human papillomavirus (HPV) infection, 220–222
  - Hunner's ulcers, 165
  - Hydronephrosis
    - differential diagnosis of, 2, 3
    - hematuria, 75, 77, 78, 82
    - megaureter, 4
    - multicystic dysplastic kidney, 5
    - posterior urethral valves, 4
    - pregnancy, 127
    - UPJ obstruction, 2, 4
    - upper-pole hydronephrosis, 4
  - Hypercalciuria
    - causes of, 97, 98
    - idiopathic
      - bone mineral density, 99
      - intestinal absorption of calcium, 99
      - pharmacological intervention, 99
      - treatment of, 99
    - primary hyperparathyroidism, 97, 98
  - Hyperoxaluria
    - enteric, 100–101
    - idiopathic, 99–100
    - primary, 101–102
  - Hyperprolactinemia, 236
  - Hypnotherapy, 285–286
- I**
- Idiopathic scrotal calcinosis, 217
  - Infections *See also* Sexually transmitted infections
    - Candida albicans*, 211–213
    - Corynebacterium minutissimum*, 214
    - tinea cruris, 212–214
  - Insomnia, 283–284
  - Interstitial cystitis (IC)
    - definition, 161
    - diagnosis
      - confusable diseases, 162, 163
      - cystoscopy and urodynamics, 163, 165
      - physical exam, 162–164
      - potassium sensitivity test, 165
      - urinalysis, 163
    - epidemiology, 161–162
    - signs and symptoms, 162
    - treatment
      - bladder-directed surgery, 170
      - clinical algorithm, 165, 166
      - intravesical instillation therapy, 168
      - non-ulcerative IC, 166–167
      - pelvic floor physical therapy, 168–169
      - pharmacotherapy, 167–168
      - sacral neuromodulation, 169
      - stress management, 169–170
      - ulcerative IC, 166
  - Intravesical heparin, interstitial cystitis, 168
  - Intravesical instillation therapy, 168
- K**
- Kallmann syndrome, 235–236
  - Kegel exercises, 150
  - Kidney cancer, 33–35

- Kidney stones**  
 cost effectiveness, 89–90  
 crystal formation theories  
   calcium phosphate deposits, 89  
   fixed particle hypothesis, 88  
   free particle hypothesis, 88  
   hyperoxaluria, 88–89  
   nephrolithiasis, 89  
 dietary factors  
   low-calcium diet, 90–91, 93  
   protein load, 90, 91  
   purine intake and uric acid excretion, 90, 92  
   renal acid excretion, 90  
   sodium ingestion, 91  
   uric acid solubility, 90, 93  
   vitamin C supplementation, 90  
 environmental factors, 92, 94  
 recurrent stone-former, evaluation of  
   serum studies, 95–96  
   stone analysis, 96–97  
   urine studies, 96  
 stone-causing syndromes  
   calcium phosphate stones and renal tubular acidosis, 106–109  
   cysteine stones, 111–112  
   drug stones, 112  
   hypercalciuria (*see* Hypercalciuria)  
   hyperoxaluria (*see* Hyperoxaluria)  
   hyperuricosuric calcium oxalate, 105–106  
   infection stones, 109–110  
   low urinary citrate, 102–104  
   medullary sponge kidney, 112, 114  
   metabolic risk factor, 114  
   uric acid stones, 104–105  
 stone clinic effect and the single stone-former, 94–95  
 supersaturation, stone composition, 88
- L**  
**Lichen nitidus (LN)**, 208  
**Lichen planus (LP)**  
 clinical signs and symptoms, 207  
 differential diagnosis, 208  
**Lichen sclerosus (LS)**, 208–209  
**Lichen simplex chronicus (LSC)**  
 clinical signs and symptoms, 205  
 hyperpigmentation and hypopigmentation, 205  
 itching, 205  
 psoriasis  
   affected sites, 205  
   clinical signs and symptoms, 205–207  
   treatment, 207  
 treatment, 205, 206  
**Lidocaine**, interstitial cystitis, 168  
**Lower urinary tract symptoms (LUTS)**  
 benign prostatic hyperplasia, 243  
 bladder outlet obstruction, 243  
 clinical evaluation  
   American Urologic Association guidelines, 246, 249  
   American Urologic Association Symptom Index, 245, 246  
   digital rectal exam (DRE), 245  
   post-void residual measurement, 249–250  
   prostate specific antigen, 245–246  
 management of, 247–248  
 pathophysiology of, 244–245  
 terminology, 243–244  
 treatment  
   invasive surgical treatment, 254–256  
   medication non-adherence, 254  
   observation, 250–251  
   pharmacologic therapy, 251–254  
   phytotherapy, 251  
 Low urinary citrate excretion  
 causes of, 102  
 dietary factors, 102–103  
 hypocitraturia, 102  
 potassium-magnesium citrate, 104  
 potassium citrate, 103–104
- M**  
**Magnetic resonance imaging (MRI)**  
 adrenal, 59–60  
 bladder and prostate, 59  
 female pelvis, 60  
 hematuria, 71–72  
 intravenous contrast, 58  
 kidney, 58  
 ureters and retroperitoneum, 58–59  
**Male infertility**  
 antisperm antibody assay, 234–235  
 assisted reproductive technology  
   intracytoplasmic sperm injection, 240  
   intrauterine insemination, 239  
   in vitro fertilization, 239–240  
 defective sperm chromatin structure, 235  
 fluorescence in situ hybridization analysis, 235  
 genetic studies, 236  
 hormone testing, 235–236  
 hypoosmotic swelling test, 235  
 medical history  
   cryptorchidism, 230  
   delayed or incomplete puberty, 230  
   environmental or industrial exposures, 231  
   excessive scrotal heat exposure, 232  
   family history, 230  
   mumps, 229–230  
   orchidopexy, 230  
   past surgical procedures, 230–231  
   performance-enhancing drugs, 232  
   recreational exposures, 231  
   respiratory infections, 230  
   sexual history, 231  
   sexually transmitted diseases, 230  
   testis atrophy, 230  
   trauma and testicular torsion, 230  
 physical examination, 232–233  
 postejaculate urinalysis, 234

- reactive oxygen species, 235
- semen analysis
  - microscopy, 234
  - reference values, 233–234
  - semen quality, 234
  - semen volume, 234
  - sperm motility, 234
- seminal fructose analysis, 234
- sperm penetration assay, 235
- sperm's interaction study, 235
- treatments
  - assisted ejaculation, 238–239
  - idiopathic infertility, 239
  - microsurgical epididymal sperm aspiration, 238
  - microsurgical reconstruction, 237
  - percutaneous epididymal sperm aspiration, 238
  - testicular sperm extraction, 238
  - transurethral resection of the ejaculatory ducts, 238
  - varicocele, 236–237
  - vasal aspiration, 237–238
- Manipulative and body-based therapy
  - autogenic training, 291
  - biofeedback, 291–292
  - chiropractic medicine, 288
  - dance, 289
  - Feldenkrais method, 290–291
  - massage therapy, 288–289
  - myofascial release, 289
  - tai chi, 290
  - yoga, 289–290
- Massage therapy, 288–289
- Melanoma, 220
- Microsurgical epididymal sperm aspiration (MESA), 238
- Mind and body medicine
  - ayurveda, 284
  - expressive meditation, 284–285
  - functional connectivity MRI, 285
  - guided imagery, 286
  - hypnotherapy, 285–286
  - music therapy, 286
  - neuromusicology, 287
  - neurophysiologic effects, 285
  - relaxation therapy, 284
  - spirituality, 287–288
- Music therapy, 286
- Myofascial release, 289
  
- N**
- Narcotics, interstitial cystitis, 168
- Natural and behavioral remedies
  - diet, 281–282
  - exercise, 283
  - herbal remedies, 281, 282
  - mindful eating, 282–283
  - sleep, 283–284
- Neuromusicology, 287
- NIH chronic prostatitis symptom index (NIH-CPSI) scores, 291
- Nocturnal enuresis, 13
  
- O**
- Obstructive uropathy, 22
- Overactive bladder (OAB), 12–13
  - advanced treatment
    - augmentation cystoplasty, 158
    - posterior tibial nerve, 157
    - sacral neuromodulation, 157
  - behavioral therapy
    - carbonated beverage restriction, 148–149
    - fluid management, 148
    - smoking cessation, 148
    - urge inhibition, 149
  - epidemiology, 139
  - pathophysiology, 138
  - pharmacologic therapy, 153–154
  
- P**
- Painful bladder syndrome (PBS), 161
- Painless scrotal masses
  - differential diagnosis, 1
  - hernia, 1–2
  - testicular tumors, 2
  - vaginalis, 1
- Pearly penile papules (PPP), 216, 217
- Pediatric potpourri
  - acute scrotum
    - appendix testis torsion, 8, 10
    - epididymoorchitis, 8
    - testicular torsion, 8, 9
  - diurnal incontinence, 12–13
  - hydronephrosis
    - differential diagnosis of, 2, 3
    - megaureter, 4
    - multicystic dysplastic kidney, 5
    - posterior urethral valves, 4
    - UPJ obstruction, 2, 4
    - upper-pole hydronephrosis, 4
  - nocturnal enuresis, 13
  - painless scrotal masses
    - differential diagnosis, 1
    - hernia, 1–2
    - testicular tumors, 2
    - vaginalis, 1
  - penis problems, 10–12
  - undescended testicles
    - bilateral impalpable testes, 7
    - clinical examination, 5
    - hypospadias, 6
    - incidence of, 5
    - orchidopexy, 7–8
    - palpable, 6
    - physical examination, 5–6
    - retractile testis, 6
    - unilateral impalpable testis, 7
    - varicocele, 13–14
- Pelvic floor muscle training (PFMT), 291–292
- Pelvic floor myalgia, 195–196
- Penile tourniquet syndrome, 223
- Pentosan polysulfate (PPS), interstitial cystitis, 167

- Percutaneous epididymal sperm aspiration (PESA), 238
- Pheochromocytoma
  - adrenal medulla, radionuclide imaging, 61
  - computed tomography, 57
  - pregnancy, 130–131
- Plasma cell balanitis, 209–211
- Postejaculate urine (PEU), 238
- Posterior tibial nerve, 157
- Potassium sensitivity test (PST), 165
- Pregnancy
  - acute abdomen and surgical considerations
    - appendicitis, 124
    - decreased somatic pain, 125
    - ectopic pregnancy, 124–125
    - uroolithiasis, 124
  - anesthetic considerations, 125
  - clinical outcomes, 131–132
  - hydronephrosis and renal rupture, 127
  - physiological alterations during
    - anticoagulation, 124
    - cardiovascular system, 123
    - gastrointestinal tract, 124
    - gravid uterus, 123
    - hydronephrosis, 124
    - increased glomerular filtration rate, 124
    - pyelonephritis, 124
    - renal plasma flow, 124
    - respiratory system, 123–124
    - total blood volume, 123
  - placenta percreta, 129
  - renal transplantation, 131
  - urinary diversion, 131
  - urinary incontinence, 132
  - urological cancer
    - incidence of, 129–130
    - pheochromocytoma, 130–131
    - renal adenocarcinoma, 130
    - transitional cell carcinomas, bladder, 130
  - urologist in the delivery room, 132
- UTI and antibiotic use
  - antimicrobial drugs toxicity, 126
  - bacteriuria, 125–126
  - intrauterine growth restriction, 126
  - nitrofurantoin and sulfonamide, 127
  - preeclampsia, 126
  - risk of prematurity, 126
- Prostate cancer
  - cons of, 31–32
  - cost effective, 31
  - early diagnosis, 30–31
  - incidence rate, 31
  - morbidity, 30
  - mortality, 31
  - predictive value
    - annual cost, 33
    - disease recurrence, 32
    - improvement in survival, 33
    - risks and complications, 32–33
  - prognosis for, 30
  - symptomatic, 30
  - treatments, 31
- Prostatitis
  - National Institutes of Health category
    - acute bacterial prostatitis, 193–194
    - asymptomatic prostatic inflammation, 199–200
    - chronic abacterial prostatitis (*see* Chronic pelvic pain syndrome (CPPS))
    - chronic bacterial prostatitis, 194
    - prevalence of, 193
- Pseudodyssynergia, 195
- Psoriasis
  - affected sites, 205
  - clinical signs and symptoms, 205–207
  - treatment, 207
- R**
- Recurrent bacterial cystitis
  - bacterial persistence, 179
  - definition, 179
  - diagnosis, 179–180
  - management
    - antibiotic prophylaxis, 180–181
    - cranberries, 181–182
    - patient counselling, 180
  - pathophysiology of, 179
- Reiki, 293
- Relaxation therapy, 284
- Renal calculi *See also* Kidney stones
  - plain-film imaging, 43
  - pregnancy
    - ESWL, 128
    - incidence of, 127
    - initial management, 127
    - percutaneous nephrostomy, 128–129
    - radiation usage, 128
- Renal staghorn calculus, 77, 79
- Resiniferotoxin (RTX), 168
- S**
- Sacral neuromodulation, 157, 169
- Sexual dysfunction
  - climax disorder
    - anorgasmia, 266
    - dysorgasmia, 268
  - ejaculatory dysfunctions, 266–268
  - prostatitis and ejaculatory pain, 268–269
  - clinical assessment
    - quality of life parameter, 260
    - questionnaires and surveys, 260–261
    - sexual desire, 260
  - clinical evaluation and management
    - laboratory tests, 270
    - patient history, 269
    - physical examination, 269
  - desire and decreased Libido
    - decreased circulating estrogen, 264
    - depression, 263
    - direct sexual partner relationship issues, 263
    - hormonal factors, 264
    - hypoactive sexual desire disorder, 263

- in men, 262
- metabolic syndrome, 262
- oral contraceptive agents, 264
- risk factors for, 262
- thyroid disease, 264
- impaired arousal
  - erectile dysfunction, 264
  - metabolic syndrome, 265–266
  - vaginal lubrication, 265
- patient evaluation, 261–262
- prevention and management
  - adverse events, 272–273
  - depression, 273–274
  - estrogen replacement therapy, 272
  - hypogonadism, 271–272
  - life style, 270–271
  - PE, medications, 273
  - prostaglandin E1, 272
  - psychological counseling, 272
  - sildenafil citrate, 272
  - tadalafil (Cialis), 272
  - testosterone replacement therapy, 272
  - vardeafil's (Levitra), 272
- sexual history, 259–260
- Sexually transmitted infections
  - herpes simplex virus, 221–222
  - human papillomavirus, 220–222
  - syphilis, 223
- Spirituality, 287–288
- Squamous cell carcinoma, 217–219
- Stress urinary incontinence (SUI)
  - behavioral therapy
    - carbonated beverage restriction, 148–149
    - fluid management, 148
    - physical activity, 149
    - smoking cessation, 148
  - clinical evaluation, 141
  - cough stress test, 145
  - cystoscopy, 146
  - lower tract imaging, 147
  - obstetric history, 142
  - pelvic floor rehabilitation, 150
  - physical examination, 143
  - urodynamic testing, 146
  - epidemiology, 139
  - overactive bladder (*see* Overactive bladder (OAB))
  - pathophysiology, 138
  - pessaries, 151
  - pharmacologic therapy, 151–153
  - surgical therapy of, 154–156
- Submucosal glomerulations, 165
- Syphilis, 223

## T

- Tai chi, 290
- Tanezumab, interstitial cystitis, 167
- Testicular cancer screening
  - high-risk groups, 38–39
  - recommendation, 39
  - self-examination, 39

- Testicular sperm extraction (TESE), 238
- Therapeutic touch, 293–294
- Transitional cell carcinoma, pregnancy, 130
- Transurethral microwave thermotherapy (TUMT), 254
- Transurethral needle ablation (TUNA), 254
- Transurethral resection of the ejaculatory ducts (TURED), 238
- Transurethral resection of the prostate (TURP), 243
- Trauma, 223

## U

- Ultrasonography
  - bladder, 49
  - Doppler sonography, 48
  - kidney, 48–50
  - prostate, 49–51
  - testis and scrotum, 50–51
  - ureter, 49
- Uncomplicated pyelonephritis, 178–179
- Undescended testicles
  - bilateral impalpable testes, 7
  - clinical examination, 5
  - hypospadias, 6
  - incidence of, 5
  - orchidopexy, 7–8
  - palpable, 6
  - physical examination, 5–6
  - retractile testis, 6
  - unilateral impalpable testis, 7
- Urinary incontinence (UI)
  - behavioral therapy
    - bladder training/timed voiding, 148
    - caffeine reduction, 148
    - dietary management, 148–149
    - fluid management, 148
    - lifestyle interventions, 149
    - obesity/weight reduction, 149
    - pelvic floor education, 147–148
    - physical activity, 149
    - relationship with diabetes, 149
    - smoking cessation, 148
    - urge inhibition, 149
  - clinical evaluation
    - bladder diary (frequency-volume chart), 144, 145
    - causative conditions, 142
    - cough stress test, 145–146
    - cystoscopy, 146
    - electronic urodynamic testing, 146
    - ICI assessment committee comparison, 141
    - indications for referral, 147
    - lower tract imaging, 147
    - physical examination, 143–144
    - presumptive diagnosis establishment, 141
    - PVR determination, 145
    - renal function tests, 146
    - screening role, 140
    - treatment plan, 142–143
    - upper tract imaging, 146
    - urinalysis, 144
  - epidemiology of, 139, 140

- Urinary incontinence (UI) (*cont.*)  
 lower urinary tract function, 138  
 pathophysiology/terminology, 138–139  
 pessaries, 151  
 physical therapy/pelvic floor rehabilitation, 149–151  
 stress urinary incontinence (*see* Stress urinary incontinence (SUI))  
 urinary urgency incontinence (*see* Urinary urgency incontinence (UUI))
- Urinary tract infections (UTIs)  
 catheter-associated UTIs  
 indwelling catheters/nosocomial infections, 183–184  
 intermittent catheterization, 184–185  
 in children  
 antibiotic chemoprophylaxis, 19–20  
 bladder and bowel function, 21  
 clinical signs and symptoms, 16, 17  
 diagnosis, 16–18  
 febrile, 18–19  
 incidence, 15–16  
 long-term consequences of, 23–24  
 mortality, 18  
 NICE clinical guidelines, 17, 18  
 nuclear medicine imaging, 21  
 pathogenesis, 16  
 renal and bladder ultrasonography, 20  
 risk factors, 21–24  
 treatment courses, 19  
 urinalysis and urine culture, 17  
 urinary tract obstruction, 18  
 voiding fluoroscopy, 20–21  
 complicated UTI  
 abnormal urinary anatomy, 183  
 fungal UTIs, 183  
 immunocompromised hosts, 183  
 neurogenic bladder, 182–183  
 recurrent bacterial cystitis (*see* Recurrent bacterial cystitis)  
 diagnosis of, 189  
 incidence of, 173, 174  
 in men, 188–189  
 novel preventative strategies, 189  
 pregnancy and antibiotic use  
 antimicrobial drugs toxicity, 126  
 bacteriuria, 125–126  
 intrauterine growth restriction, 126  
 nitrofurantoin and sulfonamide, 127  
 preeclampsia, 126  
 risk of prematurity, 126  
 sexually transmitted infections  
*Chlamydia trachomatis* infection, 186  
*Gonorrhea*, 186–187  
 mollicutes, 188  
 trichomoniasis, 187–188  
 uncomplicated UTI  
 diagnosis, 175–176  
 management, 176–179  
 pathophysiology, 174–175  
 vaccines, 189–190
- Urinary urgency incontinence (UUI)  
 advanced treatment  
 augmentation cystoplasty, 158  
 posterior tibial nerve, 157  
 sacral neuromodulation, 157  
 behavioral therapy  
 obesity/weight reduction, 149  
 physical activity, 149  
 urge inhibition, 149  
 clinical evaluation, 141  
 epidemiology, 139  
 pathophysiology, 138  
 pelvic floor rehabilitation, 150  
 pharmacologic therapy, 153–154
- Urolithiasis, 124 *See also* Kidney stones
- Urological imaging  
 computed tomography  
 adrenal, 56–57  
 hounsfield units, 52  
 kidney, 52–55  
 renal pelvis, ureters, and bladder, 56  
 retroperitoneum, 57  
 contrast media, 43–44  
 KUB, 44–45  
 magnetic resonance imaging  
 adrenal, 59–60  
 bladder and prostate, 59  
 female pelvis, 60  
 intravenous contrast, 58  
 kidney, 58  
 ureters and retroperitoneum, 58–59  
 plain-film imaging, 43  
 radionuclide imaging  
 adrenal, 61  
 bone scan, 62  
 kidney, 60–61  
 SPECT, 60  
 ultrasonography  
 bladder, 49  
 Doppler sonography, 48  
 kidney, 48–50  
 prostate, 49–51  
 testis and scrotum, 50–51  
 ureter, 49  
 urography  
 cystography, 46–47  
 intravenous, 45–46  
 retrograde urethrography, 47  
 voiding cystourethrography, 47
- V**  
 Varicocele, 13–14  
 Vesicoureteral reflux (VUR), 21–22  
 Voiding cystourethrography, 47  
 Vulvar Q-tip test, 162, 164  
 Vulvitis, 209–211
- Y**  
 Yoga, 289–290
- Z**  
 Zoon's balanitis, 209–211